Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Traf2 and Nck-interacting kinase (TNIK)
- Target
- TNIK
- Molecular classification
- Enzyme (kinase, specifically a serine/threonine-protein kinase), Regulatory component of the Wnt–beta-catenin pathway
01
Overview
Traf2 and Nck-interacting kinase (TNIK) is a serine/threonine-protein kinase and a member of the germinal center kinase (GCK) family that acts as an essential downstream effector in the canonical Wnt–beta-catenin signaling pathway. TNIK directly interacts with beta-catenin and T-cell factor 4 (TCF4), phosphorylating TCF4 and activating Wnt-driven gene transcription. TNIK is crucial for colorectal cancer cell growth and represents a promising therapeutic target, as its inhibition can block Wnt signaling output even in tumors with APC mutations. Research into TNIK inhibitors is ongoing, with several agents in preclinical or early clinical development[2][3][4][5].
- Other names
- TNIKTraf2 and Nck-interacting protein kinaseTRAF2 and NCK-interacting kinase
02
Mechanism of action
Inhibition of TNIK kinase activity, particularly its phosphorylation of TCF4, thereby blocking the transcriptional output of Wnt–beta-catenin signaling
03
Biological functions
Signal transduction (downstream effector in the Wnt–beta-catenin pathway)Regulation of transcription via phosphorylation of T-cell factor 4 (TCF4) in the nucleusCell proliferationCell survivalCell differentiationMaintenance of tissue homeostasis
04
Disease associations
Cancer, especially colorectal cancer (CRC), where TNIK activation is required for tumor cell growth and maintenance of Wnt–beta-catenin signaling even in cases with APC lossPossible roles in other malignancies involving aberrant Wnt signaling
05
Safety considerations
Potential for on-target toxicities, since the Wnt–beta-catenin pathway is critical for normal tissue homeostasis and regenerationSpecificity and selectivity of inhibitors to avoid off-target effectsLong-term safety of blocking Wnt signaling in patients (risk of impairing regenerative functions)
06
Interacting drugs
TNIK inhibitors (various small molecules in preclinical or early clinical development)
07
Biomarkers
TNIK overexpression (as a poor prognostic marker in colorectal cancer)Potentially Wnt pathway activity and APC mutation status (for patient selection and efficacy monitoring), although no robust clinical biomarkers are established
Beyond the preview
Go deeper on Traf2 and Nck-interacting kinase (TNIK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Traf2 and Nck-interacting kinase (TNIK).